Brief: Amneal Resubmits DHE Autoinjector New Drug Application And Receives U.S. FDA Approval Of Exenatide
21/11/2024 21:07
Nov 21 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL RESUBMITS DHE AUTOINJECTOR NEW DRUG APPLICATION AND
RECEIVES U.S. FDA APPROVAL OF EXENATIDE, ITS FIRST GENERIC
INJECTABLE GLP-1 AGONIST
* AMNEAL PHARMACEUTICALS INC - FDA REVIEW OF DHE
AUTOINJECTOR NDA
EXPECTED BY Q2 2025
Source text: ID:nBw6sd0Zta
Further company coverage: AMRX.O
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary